The following is a summary of “Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention,” published in the ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

The UK needs an overarching national strategy to tackle alcohol related harms, argue experts in The BMJ today, as deaths from alcohol in England reach their highest level on record.

Hanmi Pharmaceutical Senior Vice President Choi In-young, head of the R&D center, speaks to Korean media outlets at a press ...

A dietetics professor explains who should and should not embrace the latest weight-loss drugs. Holiday weight gain hits home ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Approved for use by diabetics to control blood sugar, liraglutide has also evidenced an ability to slow cognitive decline in a Phase 2b clinical trial, and reduce shrinkage of those areas of the brain ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

BMI falls short as a way to measure obesity. Doctors need to also determine whether body fat harms a person's health.